Effects of Diabetic Ketoacidosis on Visual and Verbal Neurocognitive Function in Young Patients Presenting with New-Onset Type 1 Diabetes

Ashley B. Jessup1, Mary Beth Grimley2, Echo Meyer2, Gregory P. Passmore3, Ayşenil Belger2, William H. Hoffman4, Ali S. Çalıkoğlu1

1University of North Carolina at Chapel Hill Faculty of Medicine, Division of Pediatric Endocrinology, North Carolina, United States of America
2University of North Carolina at Chapel Hill Faculty of Medicine, Department of Psychiatry, North Carolina, United States of America
3Georgia Regents University (Formerly Georgia Health Sciences University), Medical Laboratory, Imaging and Radiological Sciences, Georgia, United States of America
4Georgia Regents University, Department of Pediatric Endocrinology and Diabetes, Georgia, United States of America

ABSTRACT

Objective: To evaluate the effects of diabetic ketoacidosis (DKA) on neurocognitive functions in children and adolescents presenting with new-onset type 1 diabetes.

Methods: Newly diagnosed patients were divided into two groups: those with DKA and those without DKA (non-DKA). Following metabolic stabilization, the patients took a mini-mental status exam prior to undergoing a baseline battery of cognitive tests that evaluated visual and verbal cognitive tasks. Follow-up testing was performed 8-12 weeks after diagnosis. Patients completed an IQ test at follow-up.

Results: There was no statistical difference between the DKA and non-DKA groups neither in alertness at baseline testing nor in an IQ test at follow-up. The DKA group had significantly lower baseline scores than the non-DKA group for the visual cognitive tasks of design recognition, design memory and the composite visual memory index (VMI). At follow-up, Design Recognition remained statistically lower in the DKA group, but the design memory and the VMI tasks returned to statistical parity between the two groups. No significant differences were found in verbal cognitive tasks at baseline or follow-up between the two groups. Direct correlations were present for the admission CO2 and the visual cognitive tasks of VMI, design memory and design recognition. Direct correlations were also present for admission pH and VMI, design memory and picture memory.

Conclusion: Pediatric patients presenting with newly diagnosed type 1 diabetes and severe but uncomplicated DKA showed a definite trend for lower cognitive functioning when compared to the age-matched patients without DKA.

Key words: Diabetic ketoacidosis, cognition, dehydration, neuroinflammation

Introduction

Type 1 diabetes in children and adolescents is associated with varying degrees of diminished cognitive function, frequently involving memory, but also the subcategories of other neuropsychological domains (1,2). Studies have not always demonstrated differences in academic performance when children with type 1 diabetes are compared to siblings or classmates, suggesting that cognitive deficiencies may be subtle (3). While the pathogenesis of cognitive decline in patients with type 1 diabetes is not well understood, the pathogenesis is likely multifactorial based on numerous potential perturbators that are present during the crisis of diabetic ketoacidosis (DKA). Early age of onset (4), chronic hyperglycemia based on hemoglobin A1c (HbA1c) (5), the presence of microvascular disease (6) and decreased white matter volume have been associated with cognitive deficits (7). Diagnosis before the age seven is associated with structural and functional changes in the brain (7). Studies vary regarding the relationship between significant hypoglycemia in type 1 diabetic children/adolescents and a deleterious effect on cognition (8).

DKA is an acute metabolic and immunologic crisis that occurs in approximately 25 percent of children in the United States with new-onset type 1 diabetes (9). This life-threatening emergency results from a deficiency of insulin and insulin resistance, systemically (10) and in the brain (11). In addition, the endocrine/metabolic decompensation of DKA involves an increase in the counter-regulatory hormones (12), resulting in progressive hyperglycemia, hyperosmolar dehydration (13),...
ketoacidosis and the potential for serious electrolyte imbalances (14). Increased secretion of cortisol, a counter-regulatory hormone and potential neurotoxin, increases the prevalence of cognitive impairment in depression (15), an under-recognized co-morbidity of type 1 diabetes in children and adolescents (16). Glucocorticoid-mediated, reduced hippocampal neurogenesis and decreased cognitive function have been reported in the streptozotocin (STZ) rat (17). Of importance, the reduced hippocampal neurogenesis in STZ mice can be reversed by antidepressant treatment (18). Also, a positive correlation of C-reactive protein (CRP) with depression, unrelated to type 1 diabetes, in children and adolescents supports an interaction of emotional stress, systemic inflammation and neuroinflammation (19).

In addition to a neurotoxic effect of glucocorticoids, support for the physiologic stress of DKA and its treatment is also associated with a systemic increase of CRP (20) thus supporting roles for both physiologic and psychological stress in the pathogenesis of cognition and depression.

A recent cross-sectional retrospective study using a computer version of published tasks reported that type 1 diabetic children and adolescents who had a history of uncomplicated [no clinical cerebral edema (CE)] DKA scored lower in cognitive memory tasks of both immediate event-spatial position and event-color associations compared to an age-matched group without a history of DKA (21). In another cross-sectional retrospective study, children with type 1 diabetes were tested two to four weeks after either DKA or hypoglycemia, using the Stanford-Binet (fourth edition) and recordings of event-related memory tasks used: a) Wide range assessment of memory and learning, second edition (WRAML-2) for design memory, design recognition, picture memory and visual memory index (VMI); b) Stanford-Binet for mental age (fourth edition) and intelligence quotient (IQ); c) Wechsler Intelligence Scale for Children-IV (WISC-IV) for forward spatial span and backward spatial span and d) Delis Kaplan Executive Function System (DKEFS) for design fluency. The verbal memory and expressive language tasks used the following instruments: a) Wide range assessment of memory and learning, second edition (WRAML-2) for design memory, design recognition, picture memory and visual memory index (VMII); b) Stanford-Binet for mental age and intelligence quotient (IQ); c) Wechsler Intelligence Scale for Children-IV (WISC-IV) for forward spatial span and backward spatial span and d) Delis Kaplan Executive Function System (DKEFS) for design fluency. The verbal memory and expressive language tasks used: a) Wide range assessment of memory and learning, second edition for verbal learning, verbal learning recall and verbal learning recognition; b) WISC-IV for digit span; and c) DKEFS for verbal fluency, with subtests of letter fluency and category switching.

Methods

Patients between the ages of 7 and 18 years presenting to the North Carolina Children’s Hospital with new-onset type 1 diabetes were considered for participation. Exclusion criteria included non-English speaking patients or parents (testing materials were printed in English), chronic medication use (except hormone replacement with levothyroxine), developmental delay, learning difficulties or neuropsychological conditions as reported by parents. Fourteen patients were invited to participate between November 2011 and December 2012. DKA was managed by the pediatric intensive care unit per usual protocol, including intravenous insulin and fluid hydration. The study protocol was approved by institutional review board. Patients assented to the study along with parents’ consent. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

The initial cognitive tests were performed prior to hospital discharge. If DKA was present, initial testing occurred at least 24 hours after DKA resolution (defined as pH≥7.32 and CO₂≥18 meq/L) and transfer to the pediatric ward. Follow-up testing (T2) was eight to twelve weeks after the diagnosis of type 1 diabetes during a follow-up visit to the Pediatric Diabetes Clinic. This follow-up testing battery consisted of the same cognitive tasks administered at the initial testing as well as a shortened measure of intelligence using the Wechsler Abbreviated Scale of Intelligence (WASI-IQ).

Measurements and Instruments

Blood chemistries were collected on admission for each patient. Blood glucose was monitored prior to cognitive tests that were administered in the morning when possible. Patients completed a one-hour testing battery administered by a psychologist. The initial testing battery consisted of a Mini-Mental Status Exam (MMSE) to evaluate for alertness prior to other testing. This was followed by standard neurocognitive tests of visual and verbal cognitive tasks. The visual planning and memory tasks used the following instruments: a) Wide range assessment of memory and learning, second edition (WRAML-2) for design memory, design recognition, picture memory and visual memory index (VMII); b) Stanford-Binet for mental age and intelligence quotient; c) Wechsler Intelligence Scale for Children-IV (WISC-IV) for forward spatial span and backward spatial span and d) Delis Kaplan Executive Function System (DKEFS) for design fluency. The verbal memory and expressive language tasks used: a) Wide range assessment of memory and learning, second edition for verbal learning, verbal learning recall and verbal learning recognition; b) WISC-IV for digit span; and c) DKEFS for verbal fluency, with subtests of letter fluency and category switching.

Statistical Analysis

Standard scores and composite scores were determined for the DKA and the non-DKA groups. A Mann-Whitney U test of group medians was used to test for statistical differences.
between the DKA and non-DKA group’s demographics and admission values for HbA1c, heart rate (HR) for degree of dehydration, pH, bicarbonate (CO2); MMSE at baseline cognitive testing and WASI-IQ at follow-up cognitive testing. Statistical differences between the two groups at baseline and follow-up testing on the cognitive tasks for visual and verbal variables were established using Mann-Whitney U test of group medians. Effect size differences (ES-d) for DKA and non-DKA across the cognitive tasks for the baseline and follow-up testing were also calculated. Chi-square analysis was used to identify association between cognitive task score changes from baseline to follow-up and DKA/non-DKA patient status. Correlations were calculated between cognitive tasks measured at baseline (T1) with chemistries obtained at admission and between cognitive tasks at baseline or follow-up (T2) with pre-test blood glucose.

**Results**

All patients had uneventful recoveries. No patient required mannitol for CE or experienced blood glucose (BG) <70 mg/dL during hospitalization. Three of 14 invited patients declined to participate. Three of the four patients with DKA and five of the seven patients without DKA completed follow-up testing. Patients with DKA underwent baseline testing 29-34 hours after DKA resolution. Patients’ admission parameters and demographics are in Table 1. The DKA group presented with median labs at diagnosis consistent with DKA. Median HR in the DKA group was significantly higher than in the non-DKA group: (U=25, p=0.0472). Neither group reached the clinically significant BRIEF-Global Executive Composite (GEC) score of 70, which is suggestive of lower executive functioning. Table 2 shows mean (standard deviation) and median (range) of the standard scores of all cognitive tasks at baseline (T1) and follow-up (T2) testing.

At baseline, the DKA group scored lower on several visual tasks compared to the group without DKA. At follow-up, design recognition in the DKA group remained statistically lower than the non-DKA group; all of the other visual tasks achieved or maintained statistical parity between the two groups. There were no significant differences between the DKA and non-DKA groups at baseline or follow-up testing for any of the verbal tasks (Table 2). The correlation determinations (Table 3) show statistically significant direct relationships between

### Table 1. Descriptive variables-group demographics, metabolic/physiologic parameters, mental status and IQ for 11 subjects at admission. Statistical differences (*p<0.05) are noted

| Descriptive Variable | DKA Group (n=4) | Non-DKA Group (n=7) |
|----------------------|-----------------|---------------------|
| **Age (years) [mean (SD)]** | 12.3 (2.6) | 12.7 (2.7) |
| **Time (hours) admission to DKA resolution [mean (SD)]** | 18.8 (7.6) | --- |
| **Gender (Male/Female)** | 2/2 | 4/3 |
| **Physiologic/Metabolic Parameters at admission:** | Mean (SD) | Median (Range) |
| Hemoglobin A1c (%; mmol/mol) | | |
| 12.6 (0.83) | 12.9 (11.5-13.3) |
| Blood glucose (mg/dL) | 393 (132.8) | 410 (108.7) |
| Heart rate (HR/bpm) | 123 (28.5) | 84 (15.8) |
| 129 (85-149)\(^1\) | 81 (67-114) |
| pH | 7.23 (0.06) | 7.22 (7.16-7.31)\(^2\) |
| 7.36 (0.04) | 7.36 (7.31-7.42) |
| CO\(_2\) (mEq/L; mmol/L) | 6.25 (3.3) | 22.0 (3.3) |
| 5.5 (5-11)\(^3\) | 21.0 (18-28) |
| Mini-Mental Status Exam (baseline testing) | 25.8 (0.98) | 25.8 (0.98) |
| WASI-IQ (follow-up testing) | 107.7 (10.6) | 105.2 (11.1) |

\(^1\)Mann-Whitney U test of group medians statistically significant differences for diabetic ketoacidosis vs. non-diabetic ketoacidosis: \(^*\)p=0.0472, \(^*\)p=0.0138, \(^*\)p=0.0104. SD: standard deviation, DKA: diabetic ketoacidosis, WASI-IQ: Wechsler Abbreviated Scale of Intelligence
| Neurocognitive Tasks | Baseline Testing (T1) | Follow-up Testing (T2) |
|---------------------|-----------------------|------------------------|
|                     | DKA Mean (SD) Median (Range) | Non-DKA Mean (SD) Median (Range) | DKA Mean (SD) Median (Range) | Non-DKA Mean (SD) Median (Range) |
| **Visual Cognitive Tasks** | | | | |
| Design recognition (WRAML-2) | 8.0 (2.2) 8 (5-10) | 11.8 (3.0) 12 (8-16) | 6.7 (3.1) 6 (4-10) | 12.2 (3.5) 12 (8-17) |
| Design memory (WRAML-2) | 7.3 (2.4) 8 (4-9) | 10.6 (2.7) 10 (7-15) | 8.7 (2.3) 8 (6-10) | 10.4 (2.8) 9 (8-15) |
| Picture memory (WRAML-2) | 7.0 (4.3) 6 (3-13) | 10.7 (1.7) 10 (9-13) | 11.0 (1.0) 11 (10-12) | 11.8 (1.5) 12 (10-14) |
| VMI (design memory+picture memory) (WRAML-2) | 82.8 (18.1) 79 (67-106) | 103.9 (8.8) 106 (91-118) | 99.0 (4.6) 100 (94-103) | 106.6 (7.8) 104 (97-118) |
| Bead memory (Stanford-Binet) | 46.5 (9.4) 50 (33-53) | 46.0 (6.6) 45 (38-58) | 55.0 (3.5) 54 (51-57) | 56.0 (7.8) 57 (43-63) |
| Forward spatial span (WISC-IV) | 10.0 (2.4) 9.5 (8-13) | 9.7 (2.0) 9.5 (7-13) | 9.3 (5.1) 8 (5-15) | 8.0 (4.3) 8 (3-14) |
| Backward spatial span (WISC-IV) | 9.3 (1.7) 9.5 (7-11) | 11.67 (3.3) 12 (7-16) | 11.3 (2.3) 12 (10-14) | 9.8 (3.0) 8 (7-13) |
| Design fluency (DKEFS) | 24.8 (11.8) 24.5 (11-39) | 28.6 (9.1) 28 (18-41) | 31.7 (4.5) 32 (27-36) | 32.6 (11.2) 34 (19-48) |
| **Verbal Cognitive Tasks** | | | | |
| Verbal learning (WRAML-2) | 7.0 (5.0) 7.5 (1-12) | 10.3 (2.0) 10 (8-13) | 13.0 (0) 13 (13-13) | 12.2 (3.0) 12 (8-16) |
| Verbal learning recognition (WRAML-2) | 9.25 (4.6) 10 (3-14) | 10.1 (2.8) 9 (7-13) | 12.7 (2.3) 12 (10-14) | 11.6 (2.8) 13 (7-14) |
| Verbal learning recall (WRAML-2) | 8.5 (4.4) 9 (3-13) | 10.1 (1.2) 10 (9-12) | 11.0 (2.0) 11 (9-13) | 11.2 (4.6) 13 (5-16) |
| Digit span (WISC-IV) | 9.5 (2.9) 9.5 (6-13) | 9.4 (1.8) 10 (7-12) | 9.0 (2.6) 10 (6-11) | 10.6 (2.2) 10 (8-14) |
| **Verbal Fluency (DKEFS)** | | | | |
| Letter Fluency | 10.5 (4.7) 11.5 (4-15) | 10.9 (2.1) 11 (8-13) | 12.3 (2.5) 12 (10-15) | 10.2 (3.6) 9 (7-14) |
| Category Fluency | 9.3 (4.7) 8 (5-16) | 12.7 (3.9) 12 (8-19) | 11.7 (2.5) 12 (9-14) | 10.8 (3.3) 11 (7-14) |
| Category Switching | 8.8 (3.6) 9.5 (4-12) | 11.6 (4.1) 11 (6-17) | 10.3 (1.2) 10 (9-11) | 10.0 (3.5) 11 (6-15) |

*Mann-Whitney U test of group medians statistically significant differences for diabetic ketoacidosis vs. non-diabetic ketoacidosis: *1p=0.0354, *2p=0.0495, *3p=0.0327, *4p=0.0350.
WISC-IV: Wechsler Intelligence Scale for Children-IV; WRAML-2: wide range assessment of memory and learning, second edition; VMI: visual memory index; DKEFS: Delis Kaplan Executive Function System; DKA: diabetic ketoacidosis.
hypothesis that lower cognitive scores correlate with the DKA group.

**Discussion**

This is the first prospective study to report acute cognitive deficits in newly diagnosed children and adolescents with type 1 diabetes following correction of uncomplicated (no clinical CE) DKA. Our data support a neuronal insult during the metabolic and immunologic crisis of DKA and/or its treatment that results in acute and possibly long-term cognitive deficits. We recorded statistically lower median baseline (T1) task scores in three of the eight visual cognitive tasks tested in the newly diagnosed DKA group in comparison to an age-matched newly diagnosed non-DKA group. Whether the improvement in design memory and VMI scores three months (T2) after the correction of DKA are final new baselines is unknown, since the follow-up tasks were performed at a time when brain remodeling was possibly occurring (23). These longitudinal results differ from the retrospective, cross-sectional, solitary time point studies that reported color and position associations in children and adolescents with a history of DKA that were believed to indicate permanent cognitive deficits (21). In contrast, the follow-up (T2) testing of the median task score for design recognition in the DKA group decreased further from the baseline; however, for the non-DKA group, the score remained constant. This is in keeping with previous speculation that the neurotoxic milieu of DKA initiates a greater insult than cognitive deficit with only hyperglycemia. A pattern of decreasing cognition with time is also in keeping with the proton-magnetic resonance spectroscopy (MRS) study of recurrent episodes of DKA in a teenage patient, where the NAA/Cr ratio (neuronal insult) decreased during each DKA treatment, followed by a lesser recovery after correction of the second episode of DKA; cognitive testing was not reported (24).

The combined admission CO₂ and pH of the DKA and non-DKA groups versus the T1 results of the visual and verbal cognitive tasks (Table 3) showed significant direct correlation with six baseline tasks; design recognition, design memory, picture memory and VMI as did verbal learning and category fluency. These correlations are in keeping with the association of an acute neuronal insult in close proximity to the T1 cognitive tasks and also supportive of the direct correlation between the admission level of consciousness and admission pH at the time of DKA (25). However, it should be noted that we found no correlation between the Glasgow coma score and cognitive testing, nor a difference between the mini-alertness tests prior to cognitive testing of the DKA and non-DKA groups. In addition, the visual tasks of bead memory, picture memory and VMI and the verbal task of digit span had an inverse correlation with the pre-test (T1) BG. An inverse correlation was also present for picture memory and the pre-test (T2) BG. This inverse pre-test BG correlation with cognitive tasks

| Variable Correlation Relationship | Correlation r (p) |
|----------------------------------|------------------|
| **Baseline Cognitive Tasks (T1): Admission Chemistry** | |
| Visual Cognitive Tasks | Design recognition: CO₂ 0.6374 (0.0245) |
| | VMI: CO₂ 0.6820 (0.0208) |
| | Design memory: CO₂ 0.6348 (0.0441) |
| | Design memory: pH 0.7619 (0.0134) |
| | Picture memory: pH 0.6213 (0.0281) |
| | VMI: pH 0.8368 (0.0013) |
| | Design recognition: HR - 0.6855 (0.0199) |
| | **Verbal Cognitive Tasks** |
| | Verbal learning: CO₂ 0.6114 (0.0456) |
| | Verbal learning: pH 0.6721 (0.0234) |
| | Category fluency: pH 0.6576 (0.0279) |
| **Baseline Cognitive Tasks (T1): Pre-test BG** | |
| Visual Cognitive Tasks | Bead memory: BG - 0.8034 (0.0295) |
| | Picture memory: BG - 0.7708 (0.0425) |
| | VMI: BG - 0.7476 (0.0450) |
| | **Verbal Cognitive Tasks** |
| | Digit span: BG - 0.6744 (0.0463) |
| **Follow-up Cognitive Tasks (T2): Pre-test BG** | |
| Visual Cognitive Tasks | Picture memory: BG - 0.8881 (0.0442) |

BG: blood glucose, VMI: visual memory index

Table 3. Statistically significant (p<0.05) correlations for neurocognitive tasks measured at baseline (T1) and follow-up (T2), with chemistries and heart rate measured at admission and blood glucose at T1 or T2

Several admission chemistries and baseline measurements of both visual and verbal cognitive tasks. Correlations at baseline testing of both visual and verbal cognitive tasks with pre-test BGs indicate inverse correlations. At follow-up, the visual cognitive task of picture memory maintains its inverse correlation with pre-test BG.

Last, chi-square analysis for association of the number of cognitive score that increases between baseline and follow-up showed a significant association (χ²=3.472, p=0.0312) for the DKA group. Similarly, the cognitive variables, VMI and digit span, had significant inverse correlations with the DKA group (r=-0.6635, p=0.0260 and r=-0.7221, p=0.0121, respectively), meaning that lower cognitive scores correlate with the DKA group.
in our study was not present in the study by Ghetti et al (21). While it is not statistically significant, it is important to note that there was a large difference (effect size=2.5) between the admission HbA1c in our DKA and non-DKA groups suggesting that the cases with DKA had longer and/or more severe hyperglycemia at the time of testing. However, no correlation was found between HbA1c levels and cognitive testing in our study. In addition, there was no difference in the HbA1c pre-test values of DKA and non-DKA groups in the study by Ghetti et al (21).

Although the pathogenesis of the cognitive deficiencies associated with DKA requires further study, it has been reported that ketone bodies, by-products of metabolic dysregulation, are capable in-vitro of differentially perturbing cerebral capillary endothelial cells (CCEC) (26) and the increased release of vasoactive peptides such as endothelin-1 (ET-1) (27) and vascular endothelial growth factor (VEGF) (28) that negatively impacts cognition. Hyperlipoproteinemia (29) and toxic tryptophan catabolites (30) are additional by-products of DKA metabolic dysregulation and its treatment and thus candidates to affect cognition.

Also, 3-deoxyglucosone (31) and methylglyoxal (32), the highly reactive carbonyl compounds and neurotoxins, are precursors of advanced glycation end-products (AGE) that increase during treatment and up-regulate the inflammatory milieu of DKA (33).

These by-products are unlikely to be the sole candidates of neuronal insult/deficit since the milieu in children and adolescents with severe DKA also increases systemic and cerebral oxidative stress (34,35), SIR (36) and a likely neuronal insult. Systemic inflammatory cytokines, activation of the complement cascade including C5b-9, the membrane attack complex (37) and CRP (20) are part of the innate immune response activated by DKA that increases during treatment. Evidence for an acute neuronal insult by oxidative stress and inflammatory peptides is the immune cytochemistry (ICC) study of autopsied brains of adolescents with type 1 diabetes, where death occurred due to DKA/CE. These cases had histories of chronic poor diabetic control and poor school performance along with significant cerebral expression of oxidative/nitrosative stress and lipid peroxidation (39), as well as an acute inflammatory insult, based on glial and CCEC activation, expression of inflammatory peptides and neuronal deficits (11,38,39).

It is important to recognize that the neurotoxic immune phenotype in the brains with fatal DKA/CE is similar not only to the SIR of clinical DKA (36,37), but it also develops over time in type 1 diabetic rodent models, without the acute metabolic and immunologic insults of DKA and the occurrence of CE (40). The latter is in keeping with Hood et al’s clinical study (41) and thus DKA and CE do not appear to be prerequisites for neuronal and cognitive deficits, but rather additional severe insults. A sustained cognitive injury is also suggested based on: 1) the infrequent reports of immediate cognitive deficits following severe DKA (23); 2) the extended and increased systemic concentration of inflammatory cytokines even after correction of DKA (36); 3) the decreased density of neuroprotective GH and IGF-1 neuronal receptors in various brain regions including the hippocampus in DKA/CE (11,38,39), a region that is important for the formation and retrieval of numerous memory systems. The neuroinflammatory phenotype in the BB/W type 1 diabetic rat (40); and perhaps most importantly; 4) the activation of the AGE/receptor for advanced glycation end products (RAGE), an amplifier and perpetuator of oxidative stress and dysregulation of inflammatory pathways in the brain with or without DKA (39,40). A progressive and sustained cognitive injury also supports; 5) The observation that children whose DKA was in the more distant past had a poorer memory performance (21).

Limitations of this study are the small sample size, the short duration of follow-up and the absence of testing non-diabetic children and adolescents. Strengths of the study are that: 1) It is a prospective study involving patients of comparable ages with newly diagnosed type 1 diabetes with and without DKA; 2) It eliminates the confounding factors of hypoglycemia and microvascular disease; 3) It uses standardized cognitive testing; 4) It reports short-term follow-up testing; 5) It extends our insight into the subtleties of the early cognitive deficits in young patients with new-onset type 1 diabetes and DKA; and 6) It shows the importance of longitudinal testing.

Understanding the physiological and functional changes that accompany DKA may contribute to early detections of brain changes associated with DKA, prior to the onset of chronic debilitating effects of type 1 diabetes and may inform about the mechanisms associated with subsequent cognitive decline. Modalities to study the effect of diabetes on the brain have evolved over the years and provide new opportunities not only to examine the impact of DKA on neurocognitive dysfunction but also to understand the underlying mechanisms. Therefore, further studies in larger populations using new static and functional neuroimaging tools are needed. Nevertheless, this study serves to encourage the careful follow-up, preferably in a coordinated care setting, of all children/adolescents with type 1 diabetes, especially those who have had DKA. Whether routine neurocognitive testing can be recommended in children with type 1 diabetes as part of their follow-up is an important question that remains to be answered.

Acknowledgements

The authors are grateful to Drs. Eddythe Wiggs (NIH/ NINDS), Anders A. Sima (Wayne State School of Medicine),
Patricia Siegel (Wayne State School of Medicine), Drs. Susan Patton and David Sandberg (University of Michigan School of Medicine) for helpful discussions during the early planning of this study.

References

1. Gaudieri PA, Chen R, Greer TF, Holmes CS. Cognitive function in children with type 1 diabetes: a meta-analysis. Diabetes Care 2008;31:1892-1897.
2. Mauers N, Mazaika P, Buckingham B, Weininger S, White NH, Tsakian E, Hershey T, Cato A, Cheng RKollman C, Beck RW, Ruedy K, Aye T, Fox L, Arbelaez AM, Wilson D, Tansey M, Tamborlane W, Peng D, Marzelli M, Winer KK, Reiss AL; Diabetes Research in Children Network (DirecNet). Longitudinal assessment of neuroanatomical and cognitive differences in young children with type 1 diabetes: association with hyperglycemia. Diabetes 2015;64:1770-1779. Epub 2014 Dec 8
3. Nagui JM, Kulinskaya E, Lomax CL, Garralda ME. Neurocognitive performance in children with type 1 diabetes—a meta-analysis. J Pediatr Psychol 2009;34:271-282. Epub 2008 Jul 17
4. Ryan CM. Why is cognitive dysfunction associated with the development of diabetes early in life? The diabetes hypothesis. Pediatr Diabetes 2006;7:289-297.
5. Schoenle EJ, Schoenle D, Molinari L, Largo RH. Impaired intellectual development in children with Type I diabetes: association with HbA1c, age at diagnosis and sex. Diabetologia 2002;45:108-114.
6. van Duinkerken E, Schoonheim MM, Sanz-Arigita EJ, Uzerman RS, Moll AC, Sneek FJ, Ryan CM, Klein M, Diamant M, Barkhof F. Resting-state brain networks in type 1 diabetic patients with and without microangiopathy and their relation to cognitive functions and disease variables. Diabetes 2012;61:1814-1821. Epub 2012 Mar 20
7. Ferguson SC, Blane A, Wardlaw J, Frier BM, Perros P, McCrimmon RJ, Deary IJ. Influence of an early-onset age of type 1 diabetes on cerebral structure and cognitive function. Diabetes Care 2005;28:1431-1437.
8. Musen G, Jacobson AM, Ryan CM, Cleary PA, Waberski BH, Ferguson SC, Blane A, Wardlaw J, Frier BM, Perros P, McCrimmon RJ, Deary IJ. Effect of an early-onset age of type 1 diabetes on cerebral structure and cognitive function. Diabetes Care 2008;31:1933-1938. Epub 2008 Jul 7
9. Rews A, Klingensmith G, Davis C, Petitti DB, Pikhar C, Rodriguez B, Schwartz ID, Imperatore G, Williams D, Bolinder J, Wolf DF, DeFronzo RA, Bevilacqua S, Ferrannini E; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Impact of diabetes and its treatment on cognitive function among adolescents who participated in the diabetes control and complications trial. Diabetes Care 2008;31:1933-1938. Epub 2008 Jul 7
10. Barrett EJ, DeFronzo RA, Bevilacqua S, Ferrannini E. Insulin resistance in diabetic ketoacidosis. Diabetes 1982;31:923-928.
11. Hoffman WH, Andjelkovic AV, Zhang W, Passemore GG, Sina AA. Insulin and IGF-1 receptors, nitrotyrosin and cerebral neuronal deficits in two young patients with diabetic ketoacidosis and fatal brain edema. Brain Res 2010;1348:168-177. Epub 2010 Apr 24
12. MacGillivray MH, Voorhees ML, Putnam TL, Li PK, Schaefer PA, Bruck E. Hormone and metabolic profiles in children and adolescents with type I diabetes mellitus. Diabetes Care 1982;5(Suppl 1):38-47.
13. Durr JA, Hoffman WH, Hensen J, Sklar AH, el Gammal T, Steinhart CM. Osmoregulation of vasopressin in diabetic ketoacidosis. Am J Physiol 1990;259:723-728.
14. Roldan-Valadez E, Osorio-Peralta S, Hernandez-Martinez P, Sandoval-Gonzalez C, Casian-Castellanos G. Early MRI findings of central pontine myelinolysis following “rapid” correction of hyponatraemia during diabetic ketoacidosis. A curious pontine lesion (2003:12b). Eur Radiol 2004;14:549-551.
15. Hinkelmann K, Moritz S, Botzenhardt J, Riedesel K, Wiedemann K, Kellner M, Otte C. Cognitive impairment in major depression: association with salivary cortisol. Biol Psychiatry 2009;66:879-885. Epub 2009 Aug 26
16. Grey M, Whittemore R, Tamborlane W. Depression in type 1 diabetes in children: natural history and correlates. J Psychosom Res 2002;53:907-911.
17. Strahan AM, Arumugam TV, Cutler RG, Lee K, Egan JM, Mattson MP. Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat Neurosci 2008;11:309-317. Epub 2008 Feb 17
18. Beauquis J, Roig P, Homo-Delarche F, De Nicola A, Saravia F. Reduced hippocampal neurogenesis and number of hilar neurones in streptozotocin-induced diabetic mice: reversion by antidepressant treatment. Eur J Neurosci 2006;23:1539-1546.
19. Copeland WE, Shanahan L, Worthman C, Angold A, Costello EJ. Cumulative depression episodes predict later C-reactive protein levels: a prospective study. Biol Psychiatry 2012;71:15:21. Epub 2011 Nov 1
20. Dalton RR, Hoffman WH, Passemore GG, Martin SL. Plasma C reactive protein levels in severe diabetic ketoacidosis. Ann Clin Lab Sci 2003;33:435-442.
21. Gheti S, Lee JK, Simz CE, Demaster DM, Glaser NS. Diabetic ketoacidosis and memory dysfunction in children with type 1 diabetes. J Pediatr 2010;156:109-114.
22. Shehata G, Ettayeb A. Cognitive function and event-related potentials in children with type 1 diabetes mellitus. J Child Neurol 2010;25:469-474. Epub 2009 Sep 17
23. Holemans X, Dupuis M, Misson N, Vanderjst JF. Reversible amnesia in a Type 1 diabetic patient and bilateral hippocampal lesions on magnetic resonance imaging (MRI). Diabet Med 2001;18:761-763.
24. Wootton-Gorges SL, Buonocore MH, Caltagirone RA, Kupperman N, Glaser NS. Progressive decrease in hippocampal volume in adolescent patients with type 1 diabetes and repeated episodes of ketoacidosis without clinically apparent cerebral edema: evidence for permanent brain injury. AJNR Am J Neuroradiol 2010;31:780-781. Epub 2009 Nov 19
25. Edge JA, Roy Y, Borgomi A, Murphy NP, Ford-Adams ME, Ong KK, Dunger DB. Conscious level in children with diabetic ketoacidosis is related to severity of acidosis and not to blood glucose concentration. Pediatr Diabetes 2006;7:11-15.
26. Close TE, Cepinskas G, Omatsu T, Rose KL, Summers K, Patterson EK, Fraser DD. Diabetic ketoacidosis elicits systemic inflammation associated with cerebrovascular endothelial dysfunction. Microcirculation 2013;20:534-543.
27. Isales CM, Lin L, Hoffman WH. Acetoacetate and β-hydroxybutyrate differentially regulate endothelin-1 expression and vascular endothelial growth factor in mouse brain microvascular endothelial cells. J Diabetes Complications 1999;13:91-97.
28. Willette RN, Sauermannch C, Ezekiel M, Feuerstein G, Ohlstein EH. Effect of endothelin on cortical microvascular perfusion in rats. Stroke 1990;21:451-458.
29. van den Kommer TN, Dik MG, Comijs HC, Jonker C, Deeg DJ. Role of lipoproteins and inflammation in cognitive decline: do they interact? Neurobiol Aging 2012;33:196. Epub 2010 Jul 1

30. Carl GF, Hoffman WH, Blankenship PR, Litaker MS, Hoffman MG, Mabe PA. Diabetic ketoacidosis depletes plasma tryptophan. Endocr Res 2002;28:91-102.

31. Hoffman WH, Kappier F, Passmore GG, Mehta R. Diabetic ketoacidosis and its treatment increase plasma 3-deoxyglucosone. Clin Biochem 2003;36:269-273.

32. Turk Z, Nemet I, Varga-Defteardarović L, Car N. Elevated level of methylglyoxal during diabetic ketoacidosis and its recovery phase. Diabetes Metab 2006;32:176-180.

33. Di Loreto S, Caracciolo V, Colafarina S, Sebastiani P, Gasbarri A, Amicarelli F. Methylglyoxal induces oxidative stress-dependent cell injury and up-regulation of interleukin-1beta and nerve growth factor in cultured hippocampal neuronal cells. Brain Res 2004;1006:157-167.

34. Lee DM, Hoffman WH, Carl GF, Khichi M, Cornwell PE. Lipid peroxidation and antioxidant vitamins prior to, during, and after correction of diabetic ketoacidosis. J Diabetes Complications 2002;16:294-300.

35. Hoffman WH, Siedlak SL, Wang Y, Castellani RJ, Smith MA. Oxidative damage is present in the fatal brain edema of diabetic ketoacidosis. Brain Res 2011;1369:194-202. Epub 2010 Oct 30

36. Hoffman WH, Burek CL, Waller JL, Fisher LE, Khichi M, Mellick LB. Cytokine response to diabetic ketoacidosis and its treatment. Clin Immunol 2003;108:175-181.

37. Jerath RS, Burek CL, Hoffman WH, Passmore GG. Complement activation in diabetic ketoacidosis and its treatment. Clin Immunol 2005;116:11-17.

38. Hoffman WH, Stamatovic SM, Andjelkovic AV. Inflammatory mediators and blood brain barrier disruption in fatal brain edema of diabetic ketoacidosis. Brain Res 2009;1254:138-148. Epub 2008 Dec 11

39. Hoffman WH, Artlett CM, Zhang W, Kreipke CW, Passmore GG, Rafols JA, Sima AA. Receptor for advanced glycation end products and neuronal deficit in the fatal brain edema of diabetic ketoacidosis. Brain Res 2008;1238:154-162. Epub 2008 Aug 26

40. Sima AA, Zhang W, Kreipke CW, Rafols JA, Hoffman WH. Inflammation in diabetic encephalopathy is prevented by C-peptide. Rev Diabet Stud 2009;6:37-42. Epub 2009 May 10

41. Hood KK, Lawrence JM, Anderson A, Bell R, Dabelea D, Daniels S, Rodriguez B, Dolan LM; SEARCH for Diabetes in Youth Study Group. Metabolic and inflammatory links to depression in youth with diabetes. Diabetes Care 2012;35:2443-2446. Epub 2012 Oct 1